Clinical trials
for patients

The objective of this trial is to provide continued treatment with remibrutinib and collect long-term safety data in patients who have completed a Novartis remibrutinib trial, who have benefited from treatment, and who cannot obtain remibrutinib locally.

This study is designed to help us determine whether the study drug BMS-986517 works to treat advanced solid tumors. Experts are continuing to investigate BMS-986517 to learn about its side effects and efficacy. The study drug has not yet been approved by the Food and Drug Administration (FDA) or other regulatory agencies for the treatment of advanced solid tumors or any other medical condition.

The objective of this study is to determine whether an investigational drug called MB-CART2019.1 is more effective than a second standard chemotherapy treatment for your disease. This study will also investigate the safety of MB-CART2019.1 when administered to patients and will determine whether there are any changes in their quality of life.

The objective of this study is to determine the safety and efficacy of a new drug called “visugromab” when administered in combination with immunochemotherapy

The objective of this study is to provide continued access to elranatamab (as monotherapy) and to monitor the safety of this drug in participants with multiple myeloma who continue to show clinical benefits in the Pfizer-sponsored main study, which is scheduled to conclude.

The aim of this trial is: -To see whether the new treatment BAY 3713372 has any effect, good or bad. -To find the best dose of BAY 3713372 to give to participants. -To understand what happens to BAY 3713372 once it is in the body. -To understand how the drug affects your body. -To understand how the treatment affects your disease. -To learn how different types and amounts of food affect the way the body absorbs the trial drug.

The aim of this clinical trial is to determine the efficacy of a new drug called “visugromab” (also known as “CT-L002”) and its safety when administered in combination with nivolumab and docetaxel. CT-L002 and nivolumab help the immune system fight cancer. Docetaxel interferes with the growth of cancer cells, leading to their destruction. CT-L002 has not yet been approved for any patients outside research studies.

The aim of this study is to evaluate the efficacy, safety and tolerability of Temab-A as monotherapy in patients with locally advanced or metastatic solid tumors with MET gene amplification.

The purpose of this trial is to determine how well a new drug currently in development called visugromab (also known as CTL-002) works and whether it is safe when used in combination with nivolumab and lenvatinib.

The objective of this study is to evaluate the long-term tolerability and safety of the investigational drug TEV-56286 in people with AMS.

The primary objective of this study is to determine whether STK-012 administered together with standard-of-care treatment is more effective in treating cancer than standard-of-care treatment alone in patients with lung cancer. STK-012 is a new investigational drug being studied by the sponsor.

The objective of this trial, which involves research, is to examine the safety and efficacy of an investigational drug called LB-208. Investigational means that the investigational drug to be tested in this clinical trial has not been authorized by national drug regulatory agencies, such as the Spanish Agency of Medicines and Medical Devices.

Phase I study to determine the safety and tolerability of BI 3820768 in patients with advanced, relapsed, or treatment-refractory germ cell tumors, endometrial cancer, or ovarian cancer.

The primary objective is to compare the clinical efficacy of Rina-S with the investigator’s choice (IC) of treatment in patients with recurrent or progressive endometrial cancer (EC) following prior treatment.

The primary objective is to compare sac-TMT maintenance therapy with or without bevacizumab against standard of care (SoC) in terms of PFS as defined by RECIST 1.1, as assessed by the BICR.

The purpose of this study is to learn more about the effectiveness and safety of the study drug, volrustomig (also known as MEDI5752), when given in combination with a standard treatment for colorectal cancer.

The trial consists of 3 parts. The objective of Part 1 is to assess the safety of GEN1079 at increasing doses and to identify the doses to be used in subsequent phases. The objective of Part 2 is to refine and identify the dose that is effective while causing the fewest side effects. The goal of Part 3 is to further investigate whether GEN1079 works against the tumor and how it does so, and to continue learning about its side effects.

The purpose of this study is to determine the highest dose of BI 3819026 that people with advanced cancer can tolerate when taken alone and in combination with ezabenlimab.

The goal is to continuously monitor your well-being and safety, and to ask you if you have started a new treatment. If, for any reason, the doctor or trial staff are unable to contact you, a family member may provide information about your condition, or the trial doctor may obtain it from sources such as your medical records, national or local registries, or publicly available information, as permitted by local regulations.

The main objective of this study is to compare disease-free survival (DFS) between patients receiving TAR-210 and investigator-selected intravesical chemotherapy.